查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药物研发中人工智慧 (AI) 的全球市场：按产品、按治疗领域、按流程、按使用案例、按技术、按最终用户、按地区 - 预测到 2028 年
市场调查报告书
商品编码
1384291

药物研发中人工智慧 (AI) 的全球市场：按产品、按治疗领域、按流程、按使用案例、按技术、按最终用户、按地区 - 预测到 2028 年

Artificial Intelligence / AI in Drug Discovery Market by Offering, Process, Drug Design, Dry Lab, Wet Lab & Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 369 Pages | 订单完成后即时交付

价格
简介目录
调查范围
调查年份 2021-2028
基准年 2022年
预测期 2023-2028
考虑单位 金额（十亿美元）
部分 按产品、按治疗领域、按流程、使用案例、按技术、按最终用户、按地区
目标区域 北美、欧洲、亚太地区、南美洲、中东/非洲

药物研发领域的全球人工智慧 (AI) 市场预计将从 2023 年的 9 亿美元增加到 2028 年的 49 亿美元，预测期内复合年增长率为 40.2%。

人工智慧透过分析复杂的生物资料加速潜在药物研发标靶的识别和检验。这加速了治疗性介入的生物学相关目标的选择。机器学习等人工智慧技术可以实现快速分析和决策，减少药物研发过程所需的时间和资源。这种效率可以让您在快节奏的製药业中获得竞争优势。因此，上述因素将推动该市场的成长。另一方面，技术纯熟劳工的短缺是预测期内一定程度上限制市场成长的关键因素。

透过提供，软体和服务将在 2022 年占据市场最大的市场占有率，并且预计在预测期内将以最快的年复合成长率增长。透过我们的服务获得人工智慧技术和专业知识可以降低製药公司在药物研发中实施人工智慧的障碍。这对于不具备广泛的内部人工智慧能力的中小型企业尤其有利，使他们能够利用人工智慧的力量，而无需进行大量的前期投资。

从技术角度来看，机器学习领域在 2022 年将在全球市场中占据最大份额，预计在预测期内将以最高年复合成长率成长。机器学习可以创建预测模型来预测潜在候选药物在人体内的行为。这有助于识别成功机率最高的化合物，从而减少与不成功候选化合物相关的成本和时间。机器学习透过分析患者资料来预测个体对药物的反应，有助于制定个体化治疗策略。这使得根据遗传、分子和临床资讯製化治疗方法变得更加容易，从而产生更有效的结果，并有助于加速药物研发过程，这是支持该细分市场市场成长的因素。它已成为其中的一部分。

按使用案例，小分子设计和最佳化领域在 2022 年药物研发人工智慧市场中占据最大份额。将人工智慧应用于小分子化合物的设计和最佳化有两个主要目的。首先，它透过筛选现有化学库或透过产生从头设计来帮助识别命中和先导化合物。其次，人工智慧可以优化已识别的命中化合物，以确保结合亲和性、毒性和合成等有利特性，最终开发出更有效、更安全的候选药物。这些因素有助于开发和完善针对药物研发使用案例定制的人工智慧演算法。

到 2022 年，北美将成为药物研发人工智慧最大、成长最快的区域市场。北美拥有众多製药巨头和生物技术创新者，他们正在积极探索人工智慧在药物研发方面的能力。这些产业巨头正大力投资人工智慧驱动的研发，推动市场成长。北美拥有成熟的製药和医疗保健法律规范，可以促进人工智慧技术的整合，同时确保符合行业标准和指南。上述因素将推动北美药物研发人工智慧市场的发展。

该报告研究了药物研发发现市场中的全球人工智慧 (AI)，并透过产品、治疗领域、流程、使用案例、技术、最终用户、地区和进入市场的公司等分析了趋势。资料集等。

目录

第1章简介

第2章调查方法

第3章执行摘要

第4章重要考察

第5章市场概况

  • 介绍
  • 市场动态

第6章业界考察

  • 主要产业趋势概述
  • 供应链分析
  • 波特五力分析
  • 生态系/市场地图
  • 技术分析
  • 价格分析
  • 商业模式
  • 案例研究分析
  • 法规分析
  • 专利分析
  • 重大会议和活动（2023年第一季- 2024年季度）
  • 影响客户业务的趋势/干扰
  • 主要相关人员和采购标准
  • 人工智慧衍生的临床资产
  • 未满足的需求

第7章（按产品分类）

  • 介绍
  • 服务
  • 软体

第8章（按技术）

  • 介绍
  • 机器学习
  • 自然语言处理
  • 上下文感知处理和计算
  • 其他的

第9章（按治疗领域）

  • 介绍
  • 肿瘤学
  • 感染疾病
  • 神经科
  • 心血管疾病
  • 免疫学
  • 代谢性疾病
  • 其他的

第10章（按流程）

  • 介绍
  • 目标识别和选择
  • 目标检验
  • 命中识别和优先排序
  • 潜在客户识别/从点击中产生潜在客户
  • 潜在客户最佳化
  • 候选人的选择和检验

第11章（使用案例）

  • 介绍
  • 小分子设计与最佳化
  • 了解疾病
  • 安全性和毒性
  • 疫苗设计和最佳化
  • 抗体及其他生物设计与最佳化

第12章（按最终用户）

  • 介绍
  • 製药和生物技术公司
  • CRO
  • 研究中心以及学术和政府机构

第13章（按地区）

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第14章竞争形势

  • 主要参与企业的策略
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵
  • 新兴企业/小型企业评估矩阵
  • 竞争格局及趋势

第15章公司简介

  • 主要参与企业
    • NVIDIA CORPORATION
    • EXSCIENTIA
    • GOOGLE
    • BENEVOLENTAI
    • RECURSION
    • INSILICO MEDICINE
    • SCHRODINGER, INC.
    • MICROSOFT CORPORATION
    • ATOMWISE INC.
    • ILLUMINA, INC.
    • NUMEDII, INC.
    • XTALPI INC.
    • IKTOS
    • TEMPUS LABS
    • DEEP GENOMICS, INC.
    • VERGE GENOMICS
    • BENCHSCI
    • INSITRO
    • VALO HEALTH
    • BPGBIO, INC.
  • 其他新兴企业
    • PREDICTIVE ONCOLOGY, INC.
    • LABCORP
    • IQVIA INC.
    • TENCENT HOLDINGS LIMITED
    • CELSIUS THERAPEUTICS
    • CYTOREASON
    • OWKIN, INC.
    • CLOUD PHARMACEUTICALS
    • EVAXION BIOTECH
    • STANDIGM
    • BIOAGE LABS
    • ENVISAGENICS
    • ARIA PHARMACEUTICALS, INC.

第16章附录

简介目录
Product Code: HIT 7445

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsOffering, Therapeutic Area, Process, Use Cases, Technology, End User, Region
Regions coveredNorth America, Europe, Asia Pacific, South America, and Middle East & Africa

The artificial intelligence (AI) in drug discovery market is projected to reach USD 4.9 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 40.2% during the forecast period. AI expedites the identification and validation of potential drug targets by analyzing intricate biological data. This accelerates the selection of biologically relevant targets for therapeutic interventions. AI techniques such as machine learning enable rapid analysis and decision-making, reducing the time and resources required for drug discovery processes. This efficiency gains a competitive edge in the fast-paced pharmaceutical landscape. Therefore, aforementioned factors will drive the growth of this market. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growth to a certain extent over the forecast period.

"Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period."

Based on offering, the AI in drug discovery market is bifurcated into software and services. The2022 and segment expected to account for the largest market share of the global AI in drug discovery services market in 2022 and expected to grow fastest CAGR during the forecast period. Access to AI technology and expertise through services reduces the barriers for pharmaceutical companies to adopt AI in drug discovery. This is particularly beneficial for smaller companies without extensive in-house AI capabilities, enabling them to harness the power of AI without significant upfront investments.

"Machine learning technology segment accounted for the largest share of the global AI in drug discovery market."

Based on technology, the AI in drug discovery market is segmented into machine learning, natural language processing (NLP), context aware processing, and other technologies. The machine learning segment accounted for the largest share of the global market in 2022 and expected to grow at the highest CAGR during the forecast period. Machine learning enables the creation of predictive models that anticipate the behavior of potential drug candidates within the human body. This aids in identifying compounds with the highest likelihood of success, reducing the costs and time associated with unsuccessful candidates. Machine learning contributes to the development of personalized treatment strategies by analyzing patient data to predict individual responses to drugs. This facilitates tailoring treatments based on genetic, molecular, and clinical information, leading to more effective outcomes, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.

"Small Molecule Design and Optimization segment expected to hold the largest share of use case segment of the market in 2022."

Based on use cases, the AI in drug discovery market is divided into small molecule design and optimization, understanding disease, safety and toxicity, vaccine design and optimization, antibody and other biologics design and optimization. In 2022, the small molecule design and optimization segment accounted for the largest share of the AI in drug discovery market. AI is employed in small molecule design and optimization for two main purposes. Firstly, it aids in identifying hit-like or lead-like compounds by screening existing chemical libraries or through generative de novo design. Secondly, AI optimizes the identified hits, ensuring favorable properties like binding affinity, toxicity, and synthesis, ultimately leading to the development of more effective and safer drug candidates. These factors contribute to the development and refinement of AI algorithms tailored for drug discovery use cases.

"North America to dominate the AI in drug discovery market in 2022"

The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America hosts numerous pharmaceutical giants and biotechnology innovators that are actively exploring AI's capabilities in drug discovery. These industry leaders are investing significantly in AI-driven research and development, driving market growth. North America's well-established regulatory framework for pharmaceuticals and healthcare facilitates the integration of AI technologies while ensuring compliance with industry standards and guidelines. The above-mentioned factors will drive the market of AI in drug discovery in North America.

Breakdown of supply-side, demand side, primary interviews, by company type, designation, and region:

By Company Type:

  • By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
  • By Demand Side: Purchase Managers (45%), Head of Artificial Intelligence, Machine Learning, Drug Discovery, and Computational Molecular Design (30%) and Research Scientists (25%).
  • By Designation: C-level (31%), Director-level (25%), and Others (44%)
  • By Region: North America (45%), Europe (20%), Asia Pacific (28%), South America (4%) and Middle East & Africa (3%).

The prominent players in this market are NVIDIA Corporation (US), Exscientia (UK), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrodinger, Inc. (US), Microsoft Corporation (US), Google (US), Atomwise Inc. (US), Illumina, Inc. (US), NuMedii, Inc. (US), XtalPi Inc. (US), Iktos (France), Tempus Labs (US), Deep Genomics, Inc. (Canada), Verge Genomics (US), BenchSci (Canada), Insitro (US), Valo Health (US), BPGbio, Inc. (US), IQVIA Inc (US), Labcorp (US), Tencent Holdings Limited (China), Predictive Oncology, Inc. (US), Celsius Therapeutics (US), CytoReason (Israel), Owkin, Inc. (US), Cloud Pharmaceuticals (US), Evaxion Biotech (Denmark), Standigm (South Korea), BIOAGE (US), Envisagenics (US), and Aria Pharmaceuticals, Inc. (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage

  • The report studies the AI in drug discovery market based on offering, technology, therapeutic area, use case, process, end user, and region.
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
  • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
  • The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market.
  • The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers (growing number of cross-industry collaborations and partnerships, growing need to control drug discovery & development costs and reduce time involved in drug development, patent expiry of several drugs), restraints (shortage of AI workforce and ambiguous regulatory guidelines for medical software), opportunities (growing biotechnology industry, emerging markets, focus on developing human-aware AI systems, growth in the drugs and biologics market despite the COVID-19 pandemic), and challenges (limited availability of data sets) influencing the growth of AI in drug discovery market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the AI in drug discovery market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of AI in drug discovery solutions across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the AI in drug discovery market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the AI in drug discovery market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • FIGURE 1 AI IN DRUG DISCOVERY MARKET: MARKET SEGMENTATION
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
    • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
  • 2.2 SECONDARY SOURCES
    • 2.2.1 KEY DATA FROM SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 PRIMARY SOURCES
      • 2.3.1.1 Key data from primary sources
      • 2.3.1.2 Key industry insights
    • 2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
  • 2.4 MARKET SIZE ESTIMATION
    • FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY
    • TABLE 2 FACTOR ANALYSIS
    • FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027)
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 8 TOP-DOWN APPROACH
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.6 ASSUMPTIONS
    • 2.6.1 MARKET SIZING ASSUMPTIONS
    • 2.6.2 OVERALL STUDY ASSUMPTIONS
  • 2.7 LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET
  • 2.9 RECESSION IMPACT ANALYSIS
    • TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 5 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 6 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AI IN DRUG DISCOVERY MARKET
    • FIGURE 17 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS & PARTNERSHIPS TO DRIVE MARKET
  • 4.2 AI IN DRUG DISCOVERY MARKET: REGIONAL LANDSCAPE
    • FIGURE 18 NORTH AMERICA TO DOMINATE AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD
  • 4.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 US TO REGISTER HIGHEST REVENUE GROWTH FROM 2023 TO 2028
  • 4.4 NORTH AMERICAN AI IN DRUG DISCOVERY MARKET, BY END USER & COUNTRY, 2022
    • FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST SHARE IN NORTH AMERICA, 2022
  • 4.5 AI IN DRUG DISCOVERY MARKET, BY OFFERING
    • FIGURE 21 SERVICES TO HOLD MAJORITY MARKET SHARE IN 2028
  • 4.6 AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY
    • FIGURE 22 MACHINE LEARNING TO RETAIN MARKET LEADERSHIP TILL 2028
  • 4.7 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
    • FIGURE 23 ONCOLOGY TO DOMINATE MARKET IN 2028
  • 4.8 AI IN DRUG DISCOVERY MARKET, BY PROCESS
    • FIGURE 24 HIT-TO LEAD IDENTIFICATION/LEAD GENERATION TO DOMINATE MARKET IN 2028
  • 4.9 AI IN DRUG DISCOVERY MARKET, BY USE CASE
    • FIGURE 25 SMALL MOLECULE DESIGN & OPTIMIZATION TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD
  • 4.10 AI IN DRUG DISCOVERY MARKET, BY END USER
    • FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 27 AI IN DRUG DISCOVERY: MARKET DYNAMICS
    • TABLE 7 AI IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing cross-industry collaborations and partnerships
    • TABLE 8 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2021-2023)
      • 5.2.1.2 Growing need to reduce time and cost of drug discovery and development
      • 5.2.1.3 Patent expiry of several drugs
    • TABLE 9 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing biotechnology industry
      • 5.2.3.2 Emerging markets
      • 5.2.3.3 Focus on developing human-aware AI systems
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited availability of data sets
      • 5.2.4.2 Lack of required tools and usability

6 INDUSTRY INSIGHTS

  • 6.1 OVERVIEW OF KEY INDUSTRY TRENDS
    • 6.1.1 EVOLUTION OF AI IN DRUG DISCOVERY
    • FIGURE 28 EVOLUTION OF AI IN DRUG DISCOVERY MARKET
    • 6.1.2 COMPUTER-AIDED DRUG DESIGN AND AI
    • FIGURE 29 STRUCTURE-BASED DRUG DESIGNING: AI IN DRUG DISCOVERY MARKET
  • 6.2 SUPPLY CHAIN ANALYSIS
    • FIGURE 30 AI IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS (2022)
  • 6.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 10 AI IN DRUG DISCOVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 6.3.1 INTENSITY OF COMPETITIVE RIVALRY
    • 6.3.2 BARGAINING POWER OF BUYERS
    • 6.3.3 BARGAINING POWER OF SUPPLIERS
    • 6.3.4 THREAT OF SUBSTITUTES
    • 6.3.5 THREAT OF NEW ENTRANTS
  • 6.4 ECOSYSTEM/MARKET MAP
    • FIGURE 31 AI IN DRUG DISCOVERY MARKET ECOSYSTEM
  • 6.5 TECHNOLOGY ANALYSIS
    • FIGURE 32 AI IN DRUG DISCOVERY MARKET: CLASSIFICATION
    • 6.5.1 DRY LAB SERVICES
    • 6.5.2 WET LAB SERVICES
      • 6.5.2.1 Chemistry services
      • 6.5.2.2 BIOLOGICAL SERVICES
        • 6.5.2.2.1 Single-cell analysis
  • 6.6 PRICING ANALYSIS
    • 6.6.1 AVERAGE SELLING PRICE TRENDS, BY REGION
    • 6.6.2 INDICATIVE PRICING ANALYSIS, BY PROCESS
    • TABLE 11 AI IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS
  • 6.7 BUSINESS MODELS
    • FIGURE 33 AI IN LIFE SCIENCES: BUSINESS MODELS
    • FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS
    • FIGURE 35 SPECIALIZATION OF AI COMPANIES OVER TIME
  • 6.8 CASE STUDY ANALYSIS
    • 6.8.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA
    • 6.8.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA
  • 6.9 REGULATORY ANALYSIS
    • 6.9.1 AI IN DRUG DISCOVERY MARKET: REGULATORY LANDSCAPE, BY REGION
    • 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.10 PATENT ANALYSIS
    • FIGURE 36 TOP PATENT OWNERS AND APPLICANTS FOR AI IN DRUG DISCOVERY SOLUTIONS (JANUARY 2011-OCTOBER 2023)
    • FIGURE 37 AI IN DRUG DISCOVERY MARKET: PATENT ANALYSIS (JANUARY 2011-OCTOBER 2023)
    • FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN DRUG DISCOVERY PATENTS (JANUARY 2012-JULY 2023)
    • TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN DRUG DISCOVERY MARKET, 2021-2023
  • 6.11 KEY CONFERENCES & EVENTS (Q1 2023-Q2 2024)
  • 6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 39 REVENUE SHIFT IN AI IN DRUG DISCOVERY MARKET
  • 6.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN DRUG DISCOVERY MARKET
    • 6.13.2 BUYING CRITERIA FOR AI IN DRUG DISCOVERY MARKET
    • FIGURE 41 KEY BUYING CRITERIA FOR END USERS
  • 6.14 AI-DERIVED CLINICAL ASSETS
    • TABLE 14 KEY AI-DERIVED CLINICAL ASSETS, BY COMPANY
  • 6.15 UNMET NEEDS
    • 6.15.1 UNMET NEEDS IN AI IN DRUG DISCOVERY
    • 6.15.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY
    • 6.15.3 KEY UNMET NEEDS AND PAIN POINTS FOR AI APPLICATIONS IN SINGLE-CELL ANALYSIS FOR DRUG DISCOVERY

7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING

  • 7.1 INTRODUCTION
    • TABLE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
  • 7.2 SERVICES
    • 7.2.1 SERVICES SEGMENT TO WITNESS HIGHEST GROWTH
    • TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 SOFTWARE
    • 7.3.1 BENEFITS OF SOFTWARE IN DRUG DISCOVERY AND STRONG DEMAND AMONG END USERS TO DRIVE GROWTH
    • TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2021-2028 (USD MILLION)

8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 8.2 MACHINE LEARNING
    • TABLE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.1 DEEP LEARNING
      • 8.2.1.1 Deep learning to see growing adoption in drug discovery
    • TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.2 SUPERVISED LEARNING
      • 8.2.2.1 Applications in drug repositioning to drive market
    • TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.3 REINFORCEMENT LEARNING
      • 8.2.3.1 Potential for machines and software to automatically determine behavior to support adoption
    • TABLE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.4 UNSUPERVISED LEARNING
      • 8.2.4.1 Unpredictability to affect end-user adoption
    • TABLE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION)
    • 8.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
    • TABLE 25 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 NATURAL LANGUAGE PROCESSING
    • 8.3.1 POTENTIAL APPLICATIONS IN DATA IDENTIFICATION TO SUPPORT GROWTH
    • TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING
    • 8.4.1 RISING PROCESSING POWER, IMPROVED CONNECTIVITY TO BOOST USAGE
    • TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 OTHER TECHNOLOGIES
    • TABLE 28 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION)

9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
    • TABLE 29 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
  • 9.2 ONCOLOGY
    • 9.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH
    • TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 INFECTIOUS DISEASES
    • 9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
    • TABLE 31 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 NEUROLOGY
    • 9.4.1 NEED TO BOOST DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
    • TABLE 32 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 CARDIOVASCULAR DISEASES
    • 9.5.1 RISING DEMAND FOR CVD DRUGS TO DRIVE SEGMENT
    • TABLE 33 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
    • TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.6 IMMUNOLOGY
    • 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
    • TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.7 METABOLIC DISEASES
    • 9.7.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION
    • TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.8 OTHER THERAPEUTIC AREAS
    • TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

10 AI IN DRUG DISCOVERY MARKET, BY PROCESS

  • 10.1 INTRODUCTION
    • FIGURE 42 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2022
    • TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
  • 10.2 TARGET IDENTIFICATION & SELECTION
    • 10.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
    • TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 TARGET VALIDATION
    • 10.3.1 RISING EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE
    • TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 HIT IDENTIFICATION & PRIORITIZATION
    • 10.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION
    • TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
    • 10.5.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE
    • TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.6 LEAD OPTIMIZATION
    • 10.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION
    • TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.7 CANDIDATE SELECTION & VALIDATION
    • 10.7.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES
    • TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION)

11 AI IN DRUG DISCOVERY MARKET, BY USE CASE

  • 11.1 INTRODUCTION
    • FIGURE 43 SMALL-MOLECULE DESIGN & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    • TABLE 45 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
  • 11.2 SMALL-MOLECULE DESIGN & OPTIMIZATION
    • 11.2.1 AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH
    • TABLE 46 AI IN DRUG DISCOVERY MARKET FOR SMALL-MOLECULE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.3 UNDERSTANDING DISEASE
    • 11.3.1 RISING DATA MINING TO LINK TARGETS TO DISEASES AND DRUG REPURPOSING TO DRIVE MARKET
    • TABLE 47 AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.4 SAFETY & TOXICITY
    • 11.4.1 TOXICOLOGY AND OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO PROPEL MARKET GROWTH
    • TABLE 48 AI IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.5 VACCINE DESIGN & OPTIMIZATION
    • 11.5.1 GROWING ADOPTION OF AI FOR EPITOPE SELECTION, PREDICTION, AND BINDING TO AUGMENT MARKET GROWTH
    • TABLE 49 AI IN DRUG DISCOVERY MARKET FOR VACCINE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.6 ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION
    • 11.6.1 GROWING ADOPTION OF AI FOR ANTIBODY PROPERTY PREDICTION TO DRIVE MARKET
    • TABLE 50 AI IN DRUG DISCOVERY MARKET FOR ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION)

12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER

  • 12.1 INTRODUCTION
    • TABLE 51 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 12.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 52 INDICATIVE LIST OF DEVELOPMENTS RELATED TO AI IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
    • TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 12.3 CONTRACT RESEARCH ORGANIZATIONS
    • 12.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 54 INDICATIVE LIST OF COLLABORATIONS WITH CROS
    • TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
    • 12.4.1 SEGMENT TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD
    • TABLE 56 INDICATIVE LIST OF RESEARCH COLLABORATIONS
    • TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)

13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION

  • 13.1 INTRODUCTION
    • TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 13.2 NORTH AMERICA
    • 13.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 44 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
    • TABLE 59 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 64 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 65 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.2 US
      • 13.2.2.1 Strong economy and trend of early adoption of technologies to drive market
    • FIGURE 45 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
    • TABLE 67 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
    • TABLE 68 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 69 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 70 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 71 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 2021-2028 (USD MILLION)
    • TABLE 72 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2021-2028 (USD MILLION)
    • TABLE 73 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 74 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.3 CANADA
      • 13.2.3.1 Growing research on AI technologies and emergence of new AI-based start-ups to support market growth
    • TABLE 75 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 76 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 77 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 78 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 79 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 80 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 81 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.2.4 MEXICO
      • 13.2.4.1 Government initiatives to support market growth
    • TABLE 82 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 83 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 84 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 86 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 87 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 88 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.3 EUROPE
    • 13.3.1 EUROPE: RECESSION IMPACT
    • TABLE 89 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 91 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 95 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.2 UK
      • 13.3.2.1 UK to hold largest share in Europe
    • TABLE 97 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
    • TABLE 98 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 99 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 100 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 102 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 103 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 104 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.3 GERMANY
      • 13.3.3.1 Government support and favorable training programs to propel market growth
    • TABLE 105 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 106 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 107 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 109 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.4 FRANCE
      • 13.3.4.1 Strong government support and favorable strategies & initiatives to drive market
    • TABLE 112 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 113 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.5 ITALY
      • 13.3.5.1 Strong pharmaceutical industry to support market growth
    • TABLE 119 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 120 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 121 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.3.6 REST OF EUROPE
    • TABLE 126 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.4 ASIA PACIFIC
    • 13.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 139 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.2 JAPAN
      • 13.4.2.1 Japan to dominate APAC market
    • TABLE 141 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 142 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 143 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 145 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 146 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 147 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.3 CHINA
      • 13.4.3.1 Growing CMO market and cross-industry collaborations to drive market
    • TABLE 148 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 149 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 150 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 152 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 153 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 154 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.4 INDIA
      • 13.4.4.1 Steady adoption of AI technologies to support market growth
    • TABLE 155 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 156 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 157 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 159 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 160 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 161 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 13.4.5 REST OF ASIA PACIFIC
    • TABLE 162 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 163 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 164 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 166 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 167 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 168 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.5 SOUTH AMERICA
    • 13.5.1 SHORTAGE OF SKILLED LABOR AND GROWING REQUIREMENTS TO DRIVE AI ADOPTION
    • 13.5.2 SOUTH AMERICA: RECESSION IMPACT
    • TABLE 169 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 170 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 171 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 173 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 174 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 175 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 LIMITED COMPANY PRESENCE AND LARGE SCOPE FOR GROWTH TO FAVOR AI MARKET
    • 13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 176 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION)
    • TABLE 177 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 178 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 179 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 180 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 181 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION)
    • TABLE 182 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION)

14 COMPETITIVE LANDSCAPE

  • 14.1 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 183 OVERVIEW OF STRATEGIES ADOPTED BY KEY AI IN DRUG DISCOVERY PLAYERS, FEBRUARY 2021- MAY 2022
  • 14.2 REVENUE ANALYSIS
    • FIGURE 46 REVENUE ANALYSIS OF TOP MARKET PLAYERS, 2022
  • 14.3 MARKET SHARE ANALYSIS
    • FIGURE 47 AI IN DRUG DISCOVERY MARKET: MARKET SHARE ANALYSIS, 2022
    • TABLE 184 AI IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION
  • 14.4 COMPANY EVALUATION MATRIX
    • 14.4.1 STARS
    • 14.4.2 EMERGING LEADERS
    • 14.4.3 PERVASIVE PLAYERS
    • 14.4.4 PARTICIPANTS
    • FIGURE 48 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, 2022
    • 14.4.5 COMPANY FOOTPRINT
    • TABLE 185 USE CASE FOOTPRINT (24 COMPANIES)
    • TABLE 186 PROCESS FOOTPRINT (24 COMPANIES)
    • TABLE 187 REGION FOOTPRINT (24 COMPANIES)
    • TABLE 188 COMPANY FOOTPRINT (24 COMPANIES)
  • 14.5 START-UP/SME EVALUATION MATRIX
    • 14.5.1 PROGRESSIVE COMPANIES
    • 14.5.2 RESPONSIVE COMPANIES
    • 14.5.3 DYNAMIC COMPANIES
    • 14.5.4 STARTING BLOCKS
    • FIGURE 49 AI IN DRUG DISCOVERY MARKET: START-UP/SME EVALUATION MATRIX, 2022
    • 14.5.5 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING
    • TABLE 189 AI IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY SMES/START-UPS
    • TABLE 190 USE CASE FOOTPRINT (START-UPS/SMES)
    • TABLE 191 PROCESS FOOTPRINT (START-UPS/SMES)
    • TABLE 192 REGION FOOTPRINT (START-UPS/SMES)
    • TABLE 193 COMPANY FOOTPRINT (START-UPS/SMES)
  • 14.6 COMPETITIVE SCENARIOS AND TRENDS
    • 14.6.1 PRODUCT LAUNCHES & ENHANCEMENTS
    • TABLE 194 AI IN DRUG DISCOVERY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2021-2023
    • 14.6.2 DEALS
    • TABLE 195 AI IN DRUG DISCOVERY MARKET: DEALS, 2021-2023
    • 14.6.3 OTHER DEVELOPMENTS
    • TABLE 196 AI IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, 2021-2023

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 15.1.1 NVIDIA CORPORATION
    • TABLE 197 NVIDIA CORPORATION: COMPANY OVERVIEW
    • FIGURE 50 NVIDIA CORPORATION: COMPANY SNAPSHOT, 2022
    • TABLE 198 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 199 NVIDIA CORPORATION: PRODUCT/SERVICE LAUNCHES
    • TABLE 200 NVIDIA CORPORATION: DEALS
    • 15.1.2 EXSCIENTIA
    • TABLE 201 EXSCIENTIA: COMPANY OVERVIEW
    • FIGURE 51 EXSCIENTIA: COMPANY SNAPSHOT (2022)
    • TABLE 202 EXSCIENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 203 EXSCIENTIA: PRODUCT/SERVICE LAUNCHES
    • TABLE 204 EXSCIENTIA: DEALS
    • TABLE 205 EXSCIENTIA: OTHER DEVELOPMENTS
    • 15.1.3 GOOGLE
    • TABLE 206 GOOGLE: COMPANY OVERVIEW
    • FIGURE 52 GOOGLE: COMPANY SNAPSHOT (2022)
    • TABLE 207 GOOGLE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 208 GOOGLE: PRODUCT/SERVICE LAUNCHES
    • TABLE 209 GOOGLE: DEALS
    • TABLE 210 GOOGLE: OTHER DEVELOPMENTS
    • 15.1.4 BENEVOLENTAI
    • TABLE 211 BENEVOLENTAI: COMPANY OVERVIEW
    • FIGURE 53 BENEVOLENTAI: COMPANY SNAPSHOT (2022)
    • TABLE 212 BENEVOLENTAI: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 213 BENEVOLENTAI: DEALS
    • 15.1.5 RECURSION
    • TABLE 214 RECURSION: COMPANY OVERVIEW
    • FIGURE 54 RECURSION: COMPANY SNAPSHOT (2022)
    • TABLE 215 RECURSION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 216 RECURSION: PRODUCT/SERVICE LAUNCHES
    • TABLE 217 RECURSION: DEALS
    • TABLE 218 RECURSION: OTHER DEVELOPMENTS
    • 15.1.6 INSILICO MEDICINE
    • TABLE 219 INSILICO MEDICINE: COMPANY OVERVIEW
    • TABLE 220 INSILICO MEDICINE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 221 INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES
    • TABLE 222 INSILICO MEDICINE: DEALS
    • TABLE 223 INSILICO MEDICINE: OTHER DEVELOPMENTS
    • 15.1.7 SCHRODINGER, INC.
    • TABLE 224 SCHRODINGER, INC.: COMPANY OVERVIEW
    • FIGURE 55 SCHRODINGER, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 225 SCHRODINGER, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 226 SCHRODINGER, INC.: DEALS
    • TABLE 227 SCHRODINGER, INC.: OTHER DEVELOPMENTS
    • 15.1.8 MICROSOFT CORPORATION
    • TABLE 228 MICROSOFT CORPORATION: COMPANY OVERVIEW
    • FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 229 MICROSOFT CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 230 MICROSOFT CORPORATION: SERVICE LAUNCHES
    • TABLE 231 MICROSOFT CORPORATION: DEALS
    • 15.1.9 ATOMWISE INC.
    • TABLE 232 ATOMWISE INC.: COMPANY OVERVIEW
    • TABLE 233 ATOMWISE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 234 ATOMWISE INC.: DEALS
    • 15.1.10 ILLUMINA, INC.
    • TABLE 235 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 236 ILLUMINA, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 237 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES
    • TABLE 238 ILLUMINA, INC.: DEALS
    • 15.1.11 NUMEDII, INC.
    • TABLE 239 NUMEDII, INC.: COMPANY OVERVIEW
    • TABLE 240 NUMEDII, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 15.1.12 XTALPI INC.
    • TABLE 241 XTALPI INC.: COMPANY OVERVIEW
    • TABLE 242 XTALPI INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 243 XTALPI INC.: DEALS
    • 15.1.13 IKTOS
    • TABLE 244 IKTOS: COMPANY OVERVIEW
    • TABLE 245 IKTOS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 246 IKTOS: DEALS
    • TABLE 247 IKTOS: OTHER DEVELOPMENTS
    • 15.1.14 TEMPUS LABS
    • TABLE 248 TEMPUS LABS: COMPANY OVERVIEW
    • TABLE 249 TEMPUS LABS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 250 TEMPUS LABS: PRODUCT/SERVICE LAUNCHES
    • TABLE 251 TEMPUS LABS: DEALS
    • TABLE 252 TEMPUS LABS: OTHER DEVELOPMENTS
    • 15.1.15 DEEP GENOMICS, INC.
    • TABLE 253 DEEP GENOMICS, INC.: COMPANY OVERVIEW
    • TABLE 254 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
    • TABLE 255 DEEP GENOMICS, INC.: DEALS
    • TABLE 256 DEEP GENOMICS, INC.: OTHER DEVELOPMENTS
    • 15.1.16 VERGE GENOMICS
    • TABLE 257 VERGE GENOMICS: COMPANY OVERVIEW
    • TABLE 258 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED
    • TABLE 259 VERGE GENOMICS: DEALS
    • 15.1.17 BENCHSCI
    • TABLE 260 BENCHSCI: COMPANY OVERVIEW
    • TABLE 261 BENCHSCI: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 262 BENCHSCI: PRODUCT/SERVICE LAUNCHES
    • TABLE 263 BENCHSCI: OTHER DEVELOPMENTS
    • 15.1.18 INSITRO
    • TABLE 264 INSITRO: COMPANY OVERVIEW
    • TABLE 265 INSITRO: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 266 INSITRO: OTHER DEVELOPMENTS
    • 15.1.19 VALO HEALTH
    • TABLE 267 VALO HEALTH: COMPANY OVERVIEW
    • TABLE 268 VALO HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 269 VALO HEALTH: DEALS
    • TABLE 270 VALO HEALTH: OTHER DEVELOPMENTS
    • 15.1.20 BPGBIO, INC.
    • TABLE 271 BPGBIO, INC.: COMPANY OVERVIEW
    • TABLE 272 BPGBIO, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 273 BPGBIO, INC.: DEALS
  • 15.2 OTHER EMERGING PLAYERS
    • 15.2.1 PREDICTIVE ONCOLOGY, INC.
    • 15.2.2 LABCORP
    • 15.2.3 IQVIA INC.
    • 15.2.4 TENCENT HOLDINGS LIMITED
    • 15.2.5 CELSIUS THERAPEUTICS
    • 15.2.6 CYTOREASON
    • 15.2.7 OWKIN, INC.
    • 15.2.8 CLOUD PHARMACEUTICALS
    • 15.2.9 EVAXION BIOTECH
    • 15.2.10 STANDIGM
    • 15.2.11 BIOAGE LABS
    • 15.2.12 ENVISAGENICS
    • 15.2.13 ARIA PHARMACEUTICALS, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS